ArticleFoods (Basel, Switzerland)2025
Utilization of Yeast Cells as Alternative Carriers in the Microencapsulation of Black Chokeberry (
Article in Foods (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Plasmolyzed yeast cell system for the encapsulation ofFood science and biotechnology · 2026Article
- Advances in Yeast Glucan Particles for Oral Drug Delivery.Polymers · 2026Review
- Enhancing Stability ofFoods (Basel, Switzerland) · 2025Article
- Microencapsulation of Spent Coffee Extract WithinFoods (Basel, Switzerland) · 2025Article
- Development and Characterization of High-Nutrient Biscuits for Disaster Situations Targeting At-Risk Groups.International journal of food science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The structure of yeast cells, which are rich in bioactive compounds, makes them an attractive encapsulation vehicle due to their antioxidant, antibacterial, and antimutagenic properties. In this study, black chokeberry extract was encapsulated with different wall materials (maltodextrin, gum arabic, mixture of maltodextrin and gum arabic, plasmolyzed yeast, and non-plasmolyzed yeast) by freeze-drying. While the highest encapsulation efficiency was obtained with maltodextrin (98.82%), non-plasmolyzed yeast (86.58%) emerged as a viable alternative to gum arabic. The largest particle size was observed in plasmolyzed yeast microcapsules. Yeast-coated capsules exhibited a spheroidal morphology. Differential Scanning Calorimetry revealed high thermal stability for all microcapsules, with the gum arabic-coated microcapsules demonstrating the greatest stability. After the simulated gastric and intestinal fluid treatment, plasmolyzed yeast provided the highest retention, with 63.45% and 77.55% of phenolics, respectively. The highest 2,2-Diphenyl-1-picrylhydrazyl (DPPH) activities were found in yeast microcapsules, with no significant difference between them. In 2,2'-Azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.